- Zacks•9 days ago
The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia.
- Business Wire•9 days agoThe Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran (formerly, PCSK9si)
The Medicines Company today announced positive top-line results from the interim analysis with Day 180 follow-up for all 501 patients enrolled in the ongoing ORION-1 Phase 2 study of inclisiran, its investigational, first-in-class PCSK9 synthesis inhibitor.
- Investor's Business Daily•11 days ago
Regeneron and Sanofi could eye BioMarin and The Medicines Co. in the wake of a ban on Praluent sales.
MDCO : Summary for The Medicines Company - Yahoo Finance
The Medicines Company (MDCO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||30.12 x 100|
|Day's Range||36.57 - 38.07|
|52 Week Range||27.50 - 41.79|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-12.93|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|